#Roche has abandoned the development of one of its #obesity candidates, #emugrobart, and returned rights to originator #ChugaiPharma.
buff.ly/SnKBq26
buff.ly/SnKBq26
Roche culls myostatin candidate from obesity pipeline
Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.
buff.ly
September 28, 2026 at 2:15 PM
#Roche has abandoned the development of one of its #obesity candidates, #emugrobart, and returned rights to originator #ChugaiPharma.
buff.ly/SnKBq26
buff.ly/SnKBq26
#Roche's Japanese unit #ChugaiPharma has reached a deal to buy #RenalysPharma, a company set up to bring therapies developed elsewhere to markets in #Asia.
Chugai buys 'Asia lag' firm Renalys for $98m upfront
Chugai Pharma has reached a deal to buy Renalys Pharma, a company set up to bring therapies developed elsewhere to markets in Asia.
buff.ly
October 24, 2025 at 4:00 PM
#Roche's Japanese unit #ChugaiPharma has reached a deal to buy #RenalysPharma, a company set up to bring therapies developed elsewhere to markets in #Asia.